Lance CPA - Finch Therapeutics Chief Officer
| FNCH Stock | USD 13.41 0.04 0.30% |
Executive
Lance CPA is Chief Officer of Finch Therapeutics Group
| Age | 58 |
| Phone | 617 229 6499 |
| Web | https://www.finchtherapeutics.com |
Finch Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2194) % which means that it has lost $0.2194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6264) %, meaning that it created substantial loss on money invested by shareholders. Finch Therapeutics' management efficiency ratios could be used to measure how well Finch Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | EXECUTIVE Age | ||
| Debra Hussain | Eagle Pharmaceuticals | 57 | |
| Valentin MD | Eagle Pharmaceuticals | N/A | |
| Jeff Lovesy | Eagle Pharmaceuticals | N/A | |
| Gaozhong Zhu | Eagle Pharmaceuticals | N/A | |
| Reed McClung | Eagle Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.63 | |||
| Return On Asset | -0.22 |
Finch Therapeutics Leadership Team
Elected by the shareholders, the Finch Therapeutics' board of directors comprises two types of representatives: Finch Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Finch. The board's role is to monitor Finch Therapeutics' management team and ensure that shareholders' interests are well served. Finch Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Finch Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Lance CPA, Chief Officer | ||
| Bryan MBA, Chief Officer | ||
| Sonia Timberlake, VP Research | ||
| CFA CFA, Principal COO | ||
| Mark Smith, CEO Director | ||
| Alka Batycky, Chief Officer | ||
| JD Esq, Chief Sec | ||
| Matthew JD, Chief Officer | ||
| James Sigler, Ex CMC | ||
| James MBA, Executive CMC |
Finch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Finch Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.22 | |||
| Current Valuation | 10.74 M | |||
| Shares Outstanding | 1.61 M | |||
| Shares Owned By Insiders | 53.48 % | |||
| Shares Owned By Institutions | 11.35 % | |||
| Number Of Shares Shorted | 19.2 K | |||
| Price To Book | 0.14 X | |||
| Price To Sales | 30.46 X | |||
| Revenue | 107 K |
Currently Active Assets on Macroaxis
| VOO | Vanguard SP 500 | |
| XLK | Technology Select Sector | |
| XLV | Health Care Select | |
| QQQ | Invesco QQQ Trust | |
| XLC | Communication Services Select |
Other Information on Investing in Finch Pink Sheet
Finch Therapeutics financial ratios help investors to determine whether Finch Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Finch with respect to the benefits of owning Finch Therapeutics security.